Kilitch Drugs (India) Limited (KILITCH) AI Stock Analysis

• Market Cap: ₹4.49B
• Dividend Yield: N/A
• Average Volume (3M): 2.19K
• Price to Earnings (P/E): 34.5
• Beta (1Y): 0.87
• Revenue Growth: 32.95%
• EPS Growth: 67.39%
• Country: IN
• Employees: 168
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.27
• Shares Outstanding: 34,961,563
• 10 Day Avg. Volume: 2,304
• 30 Day Avg. Volume: 2,185
• PEG Ratio: 0.27
• Price to Book (P/B): 2.86
• Price to Sales (P/S): 2.92
• P/FCF Ratio: -19.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 7.5
• Revenue Forecast (FY): ₹2.64B

• Rating: 56 Neutral
• Price Target: ₹142.00 ▼(-60.07% Downside)
• Action: Reiterated Date: 03/28/26
• Date: Action: Reiterated 03/28/26

The score is supported by generally solid financial performance (growth and profitability with a stable balance sheet), but is held back by weak cash flow conversion, bearish technical trend signals, and a relatively high P/E without dividend support.

Positive Factors

Diversified revenue streams (domestic, exports, contract manufacturing)

Kilitch’s mix of domestic formulation sales, exports and contract/third‑party manufacturing creates multiple stable revenue channels. Structurally this reduces single‑market dependency, helps smooth capacity utilization and supports recurring revenue and margin resilience over months.

Negative Factors

Weak cash flow conversion and negative free cash flow growth

Negative free cash‑flow growth and subpar conversion of earnings into cash reflect structural cash generation issues. Elevated capex has strained liquidity, limiting the firm's ability to self‑fund growth, pay down debt, or return capital without improving operating cash conversion.

Kilitch Drugs (India) Limited Business Overview & Revenue Model

Company Description

Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malaria...

Read more

Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malaria...

How the Company Makes Money

Kilitch Drugs (India) Limited primarily makes money by selling pharmaceutical products and related services through a mix of (1) domestic sales of finished formulations to distributors, hospitals, institutions, and other pharma trade channels, and...

Read more

Kilitch Drugs (India) Limited primarily makes money by selling pharmaceutical products and related services through a mix of (1) domestic sales of finished formulations to distributors, hospitals, institutions, and other pharma trade channels, and...

Kilitch Drugs (India) Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.09B	1.98B	1.54B	1.40B	1.14B	681.28M
Gross Profit	951.14M	937.39M	731.38M	624.64M	337.44M	300.07M
EBITDA	446.60M	426.26M	287.43M	206.50M	134.13M	79.85M
Net Income	275.76M	267.01M	146.01M	104.48M	73.67M	36.71M
Balance Sheet
Total Assets	3.99B	3.13B	2.40B	2.20B	2.10B	2.03B
Cash, Cash Equivalents and Short-Term Investments	870.13M	593.98M	690.19M	591.77M	572.43M	488.49M
Total Debt	836.13M	494.24M	316.46M	221.94M	204.32M	148.04M
Total Liabilities	1.34B	1.12B	643.88M	689.41M	695.55M	736.97M
Stockholders Equity	2.66B	2.02B	1.76B	1.52B	1.39B	1.27B
Cash Flow
Free Cash Flow	-581.23M	-293.31M	-65.97M	-12.26M	-24.19M	93.61M
Operating Cash Flow	-66.20M	175.42M	-1.46M	25.86M	57.83M	456.59M
Investing Cash Flow	-514.49M	-399.47M	-95.45M	79.15M	-152.50M	-375.69M
Financing Cash Flow	813.60M	132.43M	88.07M	-7.16M	70.28M	16.14M

Kilitch Drugs (India) Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 355.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KILITCH, the sentiment is Negative. The current price of 355.6 is above the 20-day moving average (MA) of 148.19, above the 50-day MA of 158.24, and above the 200-day MA of 182.21, indicating a bearish trend. The MACD of -8.21 indicates Positive momentum. The RSI at 34.14 is Neutral, neither overbought nor oversold. The STOCH value of 25.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KILITCH.

Kilitch Drugs (India) Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VENUSREM	79 Outperform	₹13.29B	10.01	―	―	13.32%	218.38%
SAKAR	66 Neutral	₹12.94B	22.21	―	―	24.20%	55.01%
INDSWFTLAB	65 Neutral	₹11.51B	18.86	―	―	-37.70%	-19.79%
KILITCH	56 Neutral	₹4.49B	34.53	―	―	32.95%	67.39%
MEDICAMEQ	55 Neutral	₹3.29B	56.53	―	0.26%	-9.16%	49.09%
NECLIFE	52 Neutral	₹2.65B	7.63	―	―	-30.27%	-3470.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Kilitch Drugs (India) Limited Corporate Events